Core Insights - 60 Degrees Pharmaceuticals, Inc. has announced a partnership with Runway Health to enhance access to ARAKODA (tafenoquine) for malaria prevention among international travelers [1][4] - ARAKODA is the only broad-spectrum, once-weekly prescription malaria prevention medication available in the U.S. market [2][9] - The partnership will commence on April 2, 2026, and aims to provide a personalized medical treatment plan for travelers [4] Company Overview - 60 Degrees Pharmaceuticals, Inc. specializes in developing new medicines for vector-borne diseases and received FDA approval for ARAKODA in 2018 [18] - The company is headquartered in Washington, D.C., and has a subsidiary in Australia, with ARAKODA commercially available in both countries [18] Product Information - ARAKODA (tafenoquine) is indicated for malaria prophylaxis in adults aged 18 and older and has been assessed for safety in multiple clinical trials [5][8] - The drug has a long terminal half-life of approximately 16 days, allowing for less frequent dosing [7] - ARAKODA is prescribed in a loading phase of 2 x 100 mg tablets once daily for three days before travel, followed by 2 x 100 mg tablets weekly during travel [7] Partnership Details - The collaboration with Runway Health will utilize a telehealth platform to facilitate online consultations and home delivery of ARAKODA before travel [2][4] - This partnership adds a consumer-focused approach to the marketing strategy of ARAKODA, targeting individuals planning to travel to malaria-endemic regions [9]

Core Viewpoint - 60 Degree Pharmaceuticals, Inc. will implement a one-for-four (1:4) reverse stock split to comply with Nasdaq's minimum bid price requirement, effective January 20, 2026 [1][2] Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 5,148,767 to about 1,287,192 [5] - All issued and outstanding shares, options, restricted stock awards, warrants, and other securities will be adjusted accordingly, with no fractional shares issued [4] - The par value of the Common Stock will remain unchanged at $0.0001 per share, and the authorized number of shares will not change [4] Group 2: Approval Process - Stockholders approved the reverse split proposal at a special meeting on October 8, 2025, allowing the board to file an amendment to effect the split [3] - The board officially approved the reverse split on December 17, 2025, and the amendment has been filed with the Secretary of State of Delaware [3] Group 3: Company Overview - 60 Degrees Pharmaceuticals, Inc. specializes in developing new medicines for vector-borne diseases and received FDA approval for its lead product, ARAKODA, in 2018 [6] - The company is headquartered in Washington, D.C., with a subsidiary in Australia and collaborates with prominent research organizations [6]

Core Insights - 60 Degrees Pharmaceuticals, Inc. announced a study revealing that 24% of 50 patients with chronic fatigue were infected with Babesia, a parasite linked to babesiosis, suggesting a potential connection between Babesia infection and prolonged recovery times in chronic fatigue patients [1][2][9] Group 1: Study Findings - The study conducted by North Carolina State University involved 50 participants who reported chronic diseases and potential exposure to arthropod vectors, with all participants experiencing fatigue for at least six months [5] - The findings support the hypothesis that Babesia infection may be associated with chronic diseases, particularly in prolonging recovery times for patients suffering from chronic fatigue [2][4] Group 2: Ongoing Research - The B-Free Chronic Babesiosis Study is currently evaluating the efficacy and safety of the ARAKODA regimen (tafenoquine) over 90 days for resolving severe fatigue in chronic babesiosis patients, with enrollment taking place at the Icahn School of Medicine at Mount Sinai in New York [3][9] - The study's results highlight the need for further prospective controlled studies to better understand the relationship between Babesia infection and chronic diseases [4] Group 3: Babesiosis Overview - Babesiosis is a tick-borne illness caused by Babesia parasites, leading to symptoms such as fevers, chills, and fatigue, with severe cases posing life-threatening risks, especially to the elderly and immunosuppressed [7] - The incidence of babesiosis is rapidly increasing, particularly in the Northeast, with an estimated minimum annual incidence of at least 25,000 cases in the U.S., although the actual number may be significantly higher [7][8] Group 4: Company Background - 60 Degrees Pharmaceuticals, Inc. specializes in developing new medicines for vector-borne diseases and received FDA approval for its lead product, ARAKODA (tafenoquine), for malaria prevention in 2018 [10] - The company collaborates with prominent research and academic organizations in the U.S. and Australia, and is headquartered in Washington, D.C. [10]

Core Viewpoint - Shares of 60 Degrees Pharmaceuticals Inc. (SXTP) have recently declined by 19.7% over the past two weeks, but the formation of a hammer chart pattern suggests potential support and a possible trend reversal in the future [1] Technical Analysis - The hammer chart pattern indicates a minor difference between opening and closing prices, with a long lower wick, suggesting that the stock may have found support after a downtrend [4][5] - This pattern typically signals that bears may have lost control, indicating a potential trend reversal as buying interest emerges [5] Fundamental Analysis - There has been a positive trend in earnings estimate revisions for SXTP, which is considered a bullish indicator, as it often leads to price appreciation [7] - The consensus EPS estimate for the current year has increased by 20.8% over the last 30 days, indicating that analysts expect better earnings than previously predicted [8] - SXTP currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10]

Core Insights - 60 Degrees Pharmaceuticals, Inc. plans to expand its sales and marketing initiatives for ARAKODA® following positive results from a 6-month commercial pilot that indicated increased market demand among prescribers [1][2][3] Sales and Marketing Initiatives - The company will enhance its integrated digital marketing campaign to improve awareness and engagement with prescribers [2] - The number of inside sales representatives will be increased to strengthen outreach and provider relationships [8] - A partnership with GoodRx will be established to provide broader visibility of ARAKODA offers, facilitating access to savings information for patients and prescribers [8] Clinical Development - The company will add at least two clinical sites for ongoing studies related to babesiosis treatment, responding to FDA feedback regarding its Breakthrough Therapy Designation request [3][4] - The FDA acknowledged that babesiosis meets the criteria for being classified as a serious disease, suggesting the company resubmit its request with data from ongoing clinical trials [3] Product Information - ARAKODA® (tafenoquine) is approved for malaria prophylaxis in the U.S. and has been assessed for safety in five randomized trials lasting up to six months [5][6][20] - Tafenoquine offers potential advantages in less-frequent dosing for malaria prophylaxis due to its long terminal half-life of approximately 16 days [10]

Core Insights - 60 Degrees Pharmaceuticals, Inc. has initiated patient enrollment for the B-FREE Chronic Babesiosis Study, the first of its kind to evaluate a therapeutic for chronic babesiosis, which is expected to run for approximately 12 months [1][5][7] Study Overview - The B-FREE Chronic Babesiosis Study (NCT06656351) is a Phase 2 open-label study assessing the efficacy and safety of the ARAKODA® regimen of tafenoquine over 90 days for patients with chronic babesiosis [2][6] - Chronic babesiosis is characterized by disabling fatigue lasting at least six months, with laboratory confirmation of Babesia parasite exposure within the last year [3][4] - The study aims to confirm Babesia infection using validated molecular tests, potentially revealing a patient population size that could range from 4,400 to 190,000 cases annually in the U.S. [4][7] Treatment Details - The primary endpoint of the study is the resolution of fatigue, measured at Day 90 compared to baseline, using a patient-reported outcome measure [6][7] - The treatment regimen involves self-administering tafenoquine (2 x 100 mg tablets) orally with food for a total of 12 weeks [6][7] Market Need - There is currently no FDA-approved treatment for babesiosis, highlighting a significant unmet medical need [4][15] - The incidence of babesiosis is rising, particularly in the Northeast U.S., with estimates suggesting at least 25,000 cases annually, though the true number may be much higher [15][30] Company Background - 60 Degrees Pharmaceuticals, Inc. specializes in developing new medicines for vector-borne diseases and achieved FDA approval for ARAKODA® (tafenoquine) for malaria prevention in 2018 [30][18] - The company collaborates with research and academic organizations in the U.S. and Australia, and is headquartered in Washington, D.C. [30]

Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. reported significant growth in net product revenue for Q3 2025, alongside challenges in gross profit due to inventory write-offs and increased operating expenses [6][7]. Financial Highlights for Q3 2025 - Net product revenue increased by 223% year-over-year to $438 thousand [6]. - Gross profit decreased from $24 thousand to a loss of $100 thousand due to a one-time inventory write-off [6][7]. - Operating expenses rose to approximately $2.32 million, up from $2.16 million in Q3 2024, primarily due to increased advertising and sales promotion costs [7]. - Net loss attributable to common shareholders was approximately $2.44 million, or ($0.66) per share, compared to a net loss of approximately $2.27 million, or ($4.65) per share in Q3 2024 [7]. Business Highlights for Q3 2025 - ARAKODA® pharmacy deliveries increased by 14% from 1,319 boxes in Q3 2024 to 1,505 boxes in Q3 2025 [7]. - The company announced its intention to seek a Minor Use Minor Species (MUMS) designation from the FDA for treating acute canine babesiosis [7]. - A nationwide survey determined the total addressable market (TAM) for Babesiosis treatment to be up to $1.1 billion through patent expiration in 2035 [7]. - The company entered a sponsored research agreement with Tulane University to evaluate tafenoquine's activity against Borrelia and Bartonella bacteria [7]. - A partnership was established with the Icahn School of Medicine at Mount Sinai for a planned Phase II clinical study of tafenoquine in treating chronic babesiosis [7].

Revenue Performance - Product revenues for the three months ended September 30, 2025, were $437,602, compared to $135,293 for the same period in 2024, representing an increase of 224%[175] - For the nine months ended September 30, 2025, product revenues reached $702,086, up from $365,939 in 2024, indicating a growth of 92%[175] - Research revenues increased to $90,960 for the three months ended September 30, 2025, from $12,818 in 2024, marking a 609.63% increase[184] - Product revenues for the nine months ended September 30, 2025, reached $702,086, a 91.86% increase from $365,939 in the same period of 2024[195] - Research revenues surged to $390,630 for the nine months ended September 30, 2025, an increase of 804.72% from $43,177 in 2024, primarily due to a new USAMMDA contract[202] Financial Position - As of September 30, 2025, the company had cash and cash equivalents of $4,115,779, a decrease from $1,659,353 as of December 31, 2024[160] - The company raised approximately $4,281,300 in net proceeds from the July 2025 Offering, which closed on July 16, 2025[156] - Cash and cash equivalents increased by 112.09% to $2,456,426 for the nine months ended September 30, 2025, compared to $1,158,203 in 2024[212] Operating Expenses - Total operating expenses for the three months ended September 30, 2025, were $2,316,397, a 7.48% increase from $2,155,116 in 2024[186] - General and administrative expenses rose by 24.00% to $1,506,620 for the three months ended September 30, 2025, from $1,215,053 in 2024[189] - Operating expenses decreased by 19.50% to $6,272,931 for the nine months ended September 30, 2025, compared to $7,792,318 in 2024[203] Profitability and Loss - The cost of revenues for the three months ended September 30, 2025, was $537,690, compared to $111,687 in 2024, resulting in a gross loss of $100,088[175] - Gross profit for the nine months ended September 30, 2025, was $41,073, down 58.62% from $99,251 in 2024, resulting in a gross margin decrease from 27.12% to 5.85%[195][201] - The company recognized a loss of $156,445 on the change in fair value of derivative liabilities for the nine months ended September 30, 2025, compared to a gain of $1,683,034 in 2024[210] Cash Flow - Net cash used in operating activities increased by 28.60% to $(5,156,566) for the nine months ended September 30, 2025, compared to $(4,009,871) in 2024[212] - Net cash provided by investing activities was $1,625,347 for the nine months ended September 30, 2025, compared to net cash used of $1,887,016 for the same period in 2024, with proceeds of $1,708,000 from short-term investments[215] - Net cash provided by financing activities decreased to $5,979,077 for the nine months ended September 30, 2025, from $7,052,598 in the same period of 2024, mainly due to lower net proceeds from stock offerings[216] Debt and Obligations - Contractual obligations as of September 30, 2025, total $1,639,415, with $1,400,119 due within one year[168] - The company has accumulated losses to date and has not generated enough revenues to cover operating expenses, raising concerns about its ability to continue as a going concern[161] - The company plans to fund operations through third-party debt, private placements, and stock issuance until achieving profitability[164] Research and Development - Research and development expenses decreased by 13.86% to $809,777 for the three months ended September 30, 2025, compared to $940,063 in 2024[186] - The company capitalized research and development costs for its babesiosis trial at $1,109,279 for the nine months ended September 30, 2025, up from $846,323 in the same period of 2024[214] Accounting and Standards - The company recognized revenue in accordance with FASB ASC Topic No. 606, with revenue recognized when control is transferred to customers[220] - The company has elected to take advantage of the JOBS Act accounting election, allowing it to delay the adoption of certain accounting standards[233] - The company adopted ASU 2023-07 on a retrospective basis for the 2024 annual period, impacting financial statement disclosures[235]

Summary of 60 Degrees Pharmaceuticals Webinar Company Overview - **Company**: 60 Degrees Pharmaceuticals (NasdaqCM: SXTP) - **Product**: ARAKODA® (FDA-approved for malaria prevention) - **Market Cap**: Currently does not reflect historical achievements and success [15][18] Key Points and Arguments Sales Performance - ARAKODA® sales were impacted by the COVID-19 pandemic, limiting travel and thus demand [16] - Sales have increased over time, primarily driven by off-label use for chronic babesiosis [17] - Annualized gross sales are currently between $1 million and $2 million, with potential to exceed $200 million by 2035 [18] Market Potential - Malaria prevention is estimated to represent about 25% of the market potential, while chronic babesiosis could account for the majority [18] - The company aims to prove the economic opportunity and meet unmet medical needs associated with chronic babesiosis [19] Commercial Strategy - A commercial pilot program was initiated in July 2024 to increase awareness and differentiate ARAKODA® through electronic media and virtual sales representatives [22] - The pilot program includes a copay opportunity to reduce out-of-pocket costs for insured patients [22] - The company is focused on increasing awareness and managing reimbursement and market access [37][38] Research and Development - The company is conducting three clinical trials targeting different populations of babesiosis patients, with results expected in the second half of 2026 [30] - A breakthrough therapy designation request is planned for submission, with feedback expected in December [33][42] Market Valuation - The potential market for tafenoquine in babesiosis is estimated at $245 million annually, contingent on proving chronic babesiosis as a clinically significant condition [44] - The total market potential for ARAKODA® is projected to be over $200 million, with chronic babesiosis accounting for approximately 75% of that [48] Financial Outlook - The company reported a cash runway through March 2026, with updates expected in mid-November [49] - Positive cash flow timeline will be reassessed based on the outcomes of the commercial pilot data [50] Additional Important Information - ARAKODA® requires fewer pills compared to generic alternatives, which may enhance patient compliance [22] - The company is exploring the potential of tafenoquine for treating chronic Lyme disease in collaboration with Tulane University [35] - The incidence of malaria in returning travelers has been increasing, highlighting the ongoing relevance of malaria prevention [20] This summary encapsulates the critical insights from the 60 Degrees Pharmaceuticals webinar, focusing on the company's product, market potential, commercial strategies, and research initiatives.

Core Insights - 60 Degrees Pharmaceuticals has announced that the first patient in its trial for relapsing babesiosis has tested negative for the disease, indicating potential efficacy of ARAKODA (tafenoquine) in immunosuppressed patients [1][7] Company Developments - The company is conducting an expanded access study of ARAKODA in combination with conventional treatments for relapsing babesiosis, with the trial expected to confirm a high cure rate as reported by Yale in a 2024 publication [5][9] - A Breakthrough Therapy Designation request has been submitted to the FDA for tafenoquine, and the company plans to request a Type B meeting with the FDA in early 2026 to discuss the requirements for a supplementary New Drug Application (sNDA) [4][8] Clinical Study Details - The study is an open-label, multi-site trial evaluating the safety and efficacy of tafenoquine in patients with risk factors for severe disease who have previously failed conventional treatments [5][9] - The first patient tested negative for babesiosis using both the Mayo Clinic RT-PCR and an FDA-approved RNA amplification test, which is significantly more sensitive than standard tests [6][7] Disease Context - Babesiosis is a tick-borne illness that can be life-threatening, especially in elderly and immunosuppressed patients, with a rising incidence particularly in the Northeast [2] - The disease may relapse in patients with certain risk factors, and Babesia parasites can develop resistance to conventional drugs [2]